NASDAQ · OABI
OmniAb, Inc.
$5.23-$0.05 (-0.95%)
OmniAb, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.68% below the high.
Loading market information…
NASDAQ · IMDX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Insight Molecular Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Insight Molecular Diagnostics Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.24. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Insight Molecular Diagnostics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $518.00K+77.09% vs estimate |
| Q1 2025 | May 12, 2025 | -$0.26-9.47% vs estimate | $2.14M+1,576.86% vs estimate |
|---|
| Q4 2024 | Mar 24, 2025 | -$1.93-381.97% vs estimate | $1.49M+1,361.63% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.98-122.73% vs estimate | $115.00K-35.51% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.23-$0.05 (-0.95%)
OmniAb, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.68% below the high.
$3.30-$0.10 (-2.8%)
C4 Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.17% below the high.
CA$15.01-CA$0.21 (-1.38%)
Cybin Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
$4.10-$0.04 (-0.97%)
Prelude Therapeutics Incorporated’s quoted price sits in the upper half of its reported 52-week range, 39.97% below the high.
$0.60-$0.01 (-2.37%)
Invivyd, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.39% below the high.
$2.41-$0.12 (-4.74%)
PepGen Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.1% below the high.
$1.22-$0.04 (-3.17%)
Codexis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.06% below the high.
$3.25-$0.04 (-1.22%)
Armata Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.3% below the high.
